4.2 Article

Expression of microRNA-155 correlates positively with the expression of Toll-like receptor 7 and modulates hepatitis B virus via C/EBP-β in hepatocytes

期刊

JOURNAL OF VIRAL HEPATITIS
卷 22, 期 10, 页码 817-827

出版社

WILEY
DOI: 10.1111/jvh.12390

关键词

C/EBP-beta; chronic; hepatitis B virus; miRNA; Toll-like receptors

资金

  1. Indian Council of Medical Research (ICMR), New Delhi
  2. University Grants Commission (UGC), New Delhi
  3. Council of Scientific & Industrial Research (CSIR), New Delhi

向作者/读者索取更多资源

Effective recognition of viral infection and successive activation of antiviral innate immune responses are vital for host antiviral defence, which largely depends on multiple regulators, including Toll-like receptors (TLRs) and microRNAs. Several early reports suggest that specific TLR-mediated immune responses can control hepatitis B virus (HBV) replication and express differentially with disease outcome. Considering the versatile function of miR-155 in the TLR-mediated innate immune response, we aimed to study the association between miR-155 and TLRs and their subsequent impact on HBV replication using both a HBV-replicating stable cell line (HepG2.2.15) and HBV-infected liver biopsy and serum samples. Our results showed that miR-155 was suppressed during HBV infection and a subsequent positive correlation of miR-155 with TLR7 activation was noted. Further, ectopic expression of miR-155 in vitro reduced HBV load as evidenced from reduced viral DNA, mRNA and subsequently reduced level of secreted viral antigens (HBsAg and HBeAg). Our results further suggested that CCAAT/enhancer-binding protein- (C/EBP-), a positive regulator of HBV transcription, was inhibited by miR-155. Taken together, our study established a correlation between miR-155 and TLR7 during HBV infection and also demonstrated in vitro that increased miR-155 level could help to reduce HBV viral load by targeting C/EBP-.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-5/Smad pathway suppression in hepatic stellate cells

Terunao Iwanaga, Tetsuhiro Chiba, Masato Nakamura, Tatsuya Kaneko, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Tadayoshi Kogure, Sae Yumita, Takamasa Ishino, Keita Ogawa, Motoyasu Kan, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Masanori Inoue, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Shingo Nakamoto, Ryosuke Muroyama, Jun Kato, Tatsuo Kanda, Hitoshi Maruyama, Naoya Mimura, Takuya Honda, Toshihiko Murayama, Hiroyuki Nakamura, Naoya Kato

Summary: This study demonstrates that miglustat can suppress liver fibrosis by inhibiting the TGF-5/Smad pathway, reducing the expression of extracellular matrix components such as collagen. The research also shows that miglustat can both prevent the occurrence of liver fibrosis and reverse established fibrosis.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Article Gastroenterology & Hepatology

Thirty-two years' experience of treating fulminant hepatitis in a Japanese single center

Keiichi Fujiwara, Shin Yasui, Takayuki Kondo, Masato Nakamura, Makoto Arai, Tatsuo Kanda, Osamu Yokosuka, Masayuki Ohtsuka, Ryuzo Abe, Naoya Kato

Summary: The prognosis of patients with fulminant hepatitis and late-onset hepatic failure in Japan has not improved over the past 32 years, despite advancements in clinical management and liver transplantation. The increasing proportion of patients with poor prognosis and difficult-to-treat etiologies, as well as the aging population, may contribute to this lack of improvement.

HEPATOLOGY RESEARCH (2023)

Article Biotechnology & Applied Microbiology

Knockdown of NEAT1 restricts dengue virus replication by augmenting interferon alpha- inducible protein 27 via the RIG-I pathway

Jaya Saini, Umesh Thapa, Bhaswati Bandyopadhyay, Sudhanshu Vrati, Arup Banerjee

Summary: The lncRNA NEAT1 has a significant role in mitochondrial function and antiviral response. It is negatively correlated with the expression of interferon alpha-inducible protein 27 (IFI27) in dengue severity. However, the specific role of NEAT1 in dengue virus (DV) infection is still unclear.

JOURNAL OF GENERAL VIROLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Sweeping 'Metabolic Dysfunction' off the Front Foot-Deceived by the Wrong 'un: Implications of Dysmetabolism Analysis in Healthy Subjects

Shivaram P. Singh, Prajna Anirvan

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Acute Kidney Injury (AKI) at Admission Predicts Mortality in Patients With Severe Alcoholic Hepatitis (SAH)

Chitta R. Khatua, Manas K. Panigrahi, Ashok K. Choudhury, Gautam Nath, Reshu Khandelwal, Prajna Anirvan, Shivaram P. Singh

Summary: This study found that about two-thirds of ALD patients with severe alcoholic hepatitis (SAH) also had acute kidney injury (AKI), which resulted in increased mortality and prolonged hospital stay.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD

Shivaram P. Singh, Ajay Duseja, Mamun al Mahtab, Prajna Anirvan, Subrat K. Acharya, Sheikh Mohammad Fazle Akbar, Amna S. Butt, Anuradha Dassanayake, Arka De, G. P. Dhakal, Saeed Hamid, Kaushal Madan, Manas K. Panigrahi, P. N. Rao, Sanjiv Saigal, Sanjaya K. Satapathy, Shalimar, Anant Shrestha, Akash Shukla, K. C. Sudhamshu, Hasitha Wijewantha

Summary: There is ongoing debate on changing the terminology of NAFLD to MAFLD, and a meeting was held in March 2022 by experts from INASL and SAASL to discuss the appropriateness of this change. Supporters of the name change argue that NAFLD does not reflect current knowledge, and MAFLD was proposed as a more suitable term. However, it should be noted that the consensus group proposing the name change did not represent the views of gastroenterologists, hepatologists, and patients globally, as renaming a disease entity has multidimensional implications for patient care.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

NAFLD in Indians: A Myopic Yet Alarming Perspective

Shivaram P. Singh, Prajna Anirvan

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

Ajay Duseja, S. P. Singh, Arka De, Kaushal Madan, Padaki Nagaraja Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, Shalimar, Anil Arora, Anil C. Anand, Ashim Das, Ashish Kumar, Chundamannil E. Eapen, Krishnadas Devadas, Kotacherry T. Shenoy, Manas Panigrahi, Manav Wadhawan, Manish Rathi, Manoj Kumar, Narendra S. Choudhary, Neeraj Saraf, Preetam Nath, Sanjib Kar, Seema Alam, Samir Shah, Sandeep Nijhawan, Subrat K. Acharya, Vinayak Aggarwal, Vivek A. Saraswat, Yogesh K. Chawla

Summary: Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease globally and in India, and its burden is expected to increase in parallel with the ongoing epidemics of obesity and type 2 diabetes mellitus. Existing international guidelines on NAFLD fail to fully capture the Indian landscape and are difficult to incorporate into clinical practice due to sociocultural and infrastructural differences. A comprehensive review provides consensus-based guidance on the nomenclature, diagnosis, and treatment of NAFLD that is practical in the Indian setting.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2023)

Article Oncology

Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 Inhibitors

Keita Ogawa, Tetsuhiro Chiba, Masato Nakamura, Jun Arai, Jiaqi Zhang, Yaojia Ma, Na Qiang, Junjie Ao, Sae Yumita, Takamasa Ishino, Motoyasu Kan, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Hiroaki Kanzaki, Keisuke Koroki, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Shoji Matsumoto, Takayoshi Arai, Shinichiro Motohashi, Naoya Kato

Summary: In this study, the inhibition of ADAM9 was found to prevent the release of MICA and activate the immune function of NK cells. Through the screening of a chemical library, a compound called CCL347 with five benzene rings was identified, which significantly reduced sMICA levels in HCC cell lines and enhanced NK cell cytotoxicity, indicating its potential as a novel therapeutic drug for HCC.

ANTICANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Masitinib Inhibits Hepatitis A Virus Replication

Reina Sasaki-Tanaka, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Asuka Hirai-Yuki, Hiroaki Okamoto, Tatsuo Kanda

Summary: In this study, HuhT7-HAV/Luc cells were established as a suitable model for anti-HAV drug screening. Masitinib, a tyrosine kinase inhibitor, was found to reduce HAV replication and internal ribosomal entry-site (IRES) activity. It may be a potential treatment for severe HAV infection.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy

Tatsuo Kanda, Ryota Masuzaki, Reina Sasaki-Tanaka, Hirofumi Kogure, Mitsuhiko Moriyama

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Editorial Material Biochemistry & Molecular Biology

Molecular Mechanism of Chronic Viral and Non-Viral Liver Diseases

Tatsuo Kanda

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis

Shini Kanezawa, Mitsuhiko Moriyama, Tatsuo Kanda, Akiko Fukushima, Ryota Masuzaki, Reina Sasaki-Tanaka, Akiko Tsunemi, Takahiro Ueno, Noboru Fukuda, Hirofumi Kogure

Summary: Metabolic-dysfunction-associated fatty-liver disease (MAFLD) is the leading cause of liver disease worldwide. Nonalcoholic steatohepatitis (NASH) patients have a higher prevalence of small-intestinal bacterial overgrowth (SIBO). In this study, we investigated the differences in gut microbiota between stroke-prone spontaneously hypertensive-5 rats (SHRSP5) fed a normal diet (ND) or a high-fat- and high-cholesterol-containing diet (HFCD). We found an association between MAFLD and gut microbiota alteration, suggesting that targeting gut microbiota may be a potential therapeutic approach for MAFLD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Gastroenterology & Hepatology

Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan

Tatsuo Kanda, Reina Sasaki-Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian-Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto

Summary: The Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group has reviewed the recent advances in HAV research and clinical practice for HAV infection in Japan and authored comprehensive guidelines. The article covers virological findings, clinical presentation, pathogenicity, diagnostic approaches, complications, risk factors, preventive measures, and treatment modalities for hepatitis A.

HEPATOLOGY RESEARCH (2023)

Article Microbiology

Extracellular vesicles recovered from plasma of severe dengue patients induce CD4+T cell suppression through PD-L1/PD-1 interaction

Sharda Kumari, Bhaswati Bandyopadhyay, Anamika Singh, Suruchi Aggarwal, Amit Kumar Yadav, Naval Kishore Vikram, Prasenjit Guchhait, Arup Banerjee

Summary: Extracellular vesicles (EVs) derived from plasma of severe dengue patients have immunosuppressive properties on CD4+ T cells, which may contribute to T cell suppression and dengue disease progression.
暂无数据